Those with the Angelina Jolie mutation can do just like her and remove female organs to have a profound reduction in cancer ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patients with BRCA1/2-associated breast cancer have good survival outcomes and are living longer, but this raises the ...

It is recommended that prophylactic surgery should be performed as soon as possible, simply because of the early development of cancer in BRCA mutation carriers. Although ovarian cancer rarely ...

Women diagnosed with breast cancer who carry particular BRCA1 and BRCA2 genetic variants are offered surgery to remove the ovaries and fallopian tubes as this dramatically reduces their risk of ...

Do you have any thoughts about the effect of oral contraceptives on tubo-ovarian cancer risk in BRCA1/2 mutation carriers? Based on the observed age of onset of these tubo-ovarian cancers ...

Missing from current guidelines is consideration of the role of estrogens for BRCA1/BRCA2 mutation carriers ... have long-term health consequences. [2] Many patients have considered estrogen ...

LTRN A May 5th press release indicated that the FDA cleared Lantern Pharma, Inc.’s (NASDAQ:LTRN) LP-184 trial in triple ...

Germline BRCA 1 and BRCA 2 test results were available for all 450 men. These revealed 27 germline BRCA2 variants (6%), but only two germline BRCA1 variants (0.5%), and one of these probably wasn ...

Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1/2 mutations. In this combination trial patients were ...

Lantern Pharma's LP-184 advances to Phase 1b/2 trial in TNBC after FDA clearance, adding to its Fast Track and Rare Pediatric Disease designations.

The combination of the PARP inhibitor olaparib and the PD-1 inhibitor pembrolizumab showed initial antitumor activity with no new safety signals in a molecularly matched, tumor-agnostic trial, ...